These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1223 related items for PubMed ID: 25388165

  • 1. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T, Ishii G, Goto K, Neri S, Hashimoto H, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Iida S, Niimi A, Nagai K, Ohe Y, Ochiai A.
    Clin Cancer Res; 2015 Feb 01; 21(3):642-51. PubMed ID: 25388165
    [Abstract] [Full Text] [Related]

  • 2. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
    Hurbin A, Wislez M, Busser B, Antoine M, Tenaud C, Rabbe N, Dufort S, de Fraipont F, Moro-Sibilot D, Cadranel J, Coll JL, Brambilla E.
    J Pathol; 2011 Sep 01; 225(1):83-95. PubMed ID: 21598249
    [Abstract] [Full Text] [Related]

  • 3. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J, Zhang L, Zhu H, Pan W, Zhang N, Li Y, Yang M.
    DNA Cell Biol; 2018 Nov 01; 37(11):903-908. PubMed ID: 30277797
    [Abstract] [Full Text] [Related]

  • 4. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH, Kim HR, Cho BC, Bae MK, Kim EY, Lee CY, Lee JS, Kang DR, Kim JH.
    Lung Cancer; 2014 May 01; 84(2):196-202. PubMed ID: 24629638
    [Abstract] [Full Text] [Related]

  • 5. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A.
    Int J Cancer; 2014 Jun 01; 134(11):2560-71. PubMed ID: 24374738
    [Abstract] [Full Text] [Related]

  • 6. CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors.
    Ishibashi M, Neri S, Hashimoto H, Miyashita T, Yoshida T, Nakamura Y, Udagawa H, Kirita K, Matsumoto S, Umemura S, Yoh K, Niho S, Tsuboi M, Masutomi K, Goto K, Ochiai A, Ishii G.
    Sci Rep; 2017 Apr 21; 7():46662. PubMed ID: 28429795
    [Abstract] [Full Text] [Related]

  • 7. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.
    Han JY, Lee KH, Kim SW, Min YJ, Cho E, Lee Y, Lee SH, Kim HY, Lee GK, Nam BH, Han H, Jung J, Lee JS.
    Cancer Res Treat; 2017 Jan 21; 49(1):10-19. PubMed ID: 27188206
    [Abstract] [Full Text] [Related]

  • 8. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
    Dong S, Qu X, Li W, Zhong X, Li P, Yang S, Chen X, Shao M, Zhang L.
    J Hematol Oncol; 2015 Apr 29; 8():43. PubMed ID: 25925741
    [Abstract] [Full Text] [Related]

  • 9. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y.
    Oncologist; 2016 Feb 29; 21(2):156-64. PubMed ID: 26768482
    [Abstract] [Full Text] [Related]

  • 10. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G, Xie X, Sun D, Geng J, Fu F, Zhang L, Wang H.
    Int J Clin Exp Pathol; 2015 Feb 29; 8(7):8603-6. PubMed ID: 26339441
    [Abstract] [Full Text] [Related]

  • 11. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ, Hung JY, Tsai MJ, Wu KL, Liu TC, Chou SH, Lee JY, Hsu JS, Huang MS, Chong IW.
    BMC Pharmacol Toxicol; 2017 May 10; 18(1):21. PubMed ID: 28486985
    [Abstract] [Full Text] [Related]

  • 12. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S.
    Clin Cancer Res; 2009 Nov 01; 15(21):6630-8. PubMed ID: 19843665
    [Abstract] [Full Text] [Related]

  • 13. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
    Ni J, Zhou LL, Ding L, Zhao X, Cao H, Fan F, Li H, Lou R, Du Y, Dong S, Liu S, Wang Z, Ma R, Wu J, Feng J.
    Exp Cell Res; 2017 Dec 15; 361(2):246-256. PubMed ID: 29080795
    [Abstract] [Full Text] [Related]

  • 14. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
    Wang YS, Wang YH, Xia HP, Zhou SW, Schmid-Bindert G, Zhou CC.
    Asian Pac J Cancer Prev; 2012 Dec 15; 13(1):255-60. PubMed ID: 22502680
    [Abstract] [Full Text] [Related]

  • 15. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
    Yoshida T, Ishii G, Goto K, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Nagai K, Ohe Y, Ochiai A.
    J Cancer Res Clin Oncol; 2013 Oct 15; 139(10):1691-700. PubMed ID: 23974272
    [Abstract] [Full Text] [Related]

  • 16. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J, Kwak KJ, Wu Z, Yang D, Li J, Chang M, Song Y, Zeng H, Lee LJ, Hu J, Bai C.
    Cell Physiol Biochem; 2018 Oct 15; 47(5):1909-1924. PubMed ID: 29961070
    [Abstract] [Full Text] [Related]

  • 17. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC, Tseng GC, Tu CY, Chen WC, Liao WC, Chen WC, Li CH, Chen HJ, Hsia TC.
    Lung Cancer; 2017 Aug 15; 110():56-62. PubMed ID: 28676220
    [Abstract] [Full Text] [Related]

  • 18. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, Koh Y, Keam B, Min HS, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS, Lee SH, Kim JI.
    Ann Oncol; 2013 Aug 15; 24(8):2080-7. PubMed ID: 23559152
    [Abstract] [Full Text] [Related]

  • 19. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK.
    Lung Cancer; 2014 Aug 15; 85(2):161-7. PubMed ID: 24857785
    [Abstract] [Full Text] [Related]

  • 20. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Cha YK, Lee HY, Ahn MJ, Choi YL, Lee JH, Park K, Lee KS.
    Clin Lung Cancer; 2015 May 15; 16(3):228-36. PubMed ID: 25499173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.